FGFR3 Antibody

Catalog Number:

33373

Amount:

100μg

Price:

$319

Swiss-Prot No:

Swiss-Prot: P22607
NCBI Gene ID: 2261

Form of Antibody:

Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Storage/Stability:

Immunogen:

Synthesized peptide derived from human FGFR3.

Purification:

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Specificity/Sensitivity:

The antibody detects endogenous levels of total FGFR3 protein.

Applications:

WB IHC

Background:

Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis. Plays an essential role in the regulation of chondrocyte differentiation, proliferation and apoptosis, and is required for normal skeleton development. Regulates both osteogenesis and postnatal bone mineralization by osteoblasts. Promotes apoptosis in chondrocytes, but can also promote cancer cell proliferation. Required for normal development of the inner ear. Phosphorylates PLCG1, CBL and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Plays a role in the regulation of vitamin D metabolism. Mutations that lead to constitutive kinase activation or impair normal FGFR3 maturation, internalization and degradation lead to aberrant signaling. Over-expressed or constitutively activated FGFR3 promotes activation of PTPN11/SHP2, STAT1, STAT5A and STAT5B. Secreted isoform 3 retains its capacity to bind FGF1 and FGF2 and hence may interfere with FGF signaling.

Jing Chen, Blood, Jul 2005; 106: 328 - 337.
Qing Zhang, Diabetes, Jan 2007; 56: 96 - 106.
Nigel P. Pringle, Development, Jan 2003; 130: 93.
Gladys Valverde-Franco, Hum. Mol. Genet., Feb 2004; 13: 271 - 284.

References:

appl_detail:

Western blotting: 1:500~1:3000
Immunohistochemistry: 1:50~1:100

Datasheet PDF